Q4 2021 Results
Company overview
Pharmaceuticals
Participants
Financial performance
Oncology
Financial review
Conclusion
Innovation: Pipeline overview
Novartis pipeline in Phase 1 (2 of 2)
Immunology
Code
Respiratory & Allergy
Name
Mechanism
Indication(s)
Code
Name
Mechanism
FIA586 FIA586
MHS552 MHS552
MHV370 MHV370
Non-alcoholic steatohepatitis (NASH)
Autoimmune indications
LTP001 LTP001
NCJ424
NCJ424
NG1226 NG1226
Systemic lupus erythematosus
Tendinopathy
Neuroscience
Appendix
Innovation: Clinical trials
32 lead indications
Lead indication
Indication(s)
Respiratory diseases
Respiratory diseases
Cardiovascular, Renal, Metabolism
Mechanism
Indication(s)
Obesity related diseases
Code
Name
Mechanism
Indication(s)
Code Name
MBL949 MBL949
NIO752 NIO752
Tau antagonist
Progressive supranuclear palsy
Global Health
Ophthalmology
Code
Name
Mechanism
Indication(s)
Code
EYU688
KAF156
MHU650 MHU650
Diabetic eye diseases
INE963
Name
EYU688
ganaplacide
INE963
Mechanism
NS4B inhibitor
60 Investor Relations | Q4 2021 Results
Indication(s)
Dengue
Malaria prophylaxis
Malaria, uncomplicated
NOVARTIS | Reimagining MedicineView entire presentation